www.nature.com/bjp

GLC-3: a novel fipronil and BIDN-sensitive, but picrotoxinininsensitive, L-glutamate-gated chloride channel subunit from *Caenorhabditis elegans*

¹Lucy Horoszok, ²Valérie Raymond, ²David B. Sattelle & *,¹Adrian J. Wolstenholme

¹Department of Biology and Biochemistry, University of Bath, Claverton Down, Bath BA2 7AY and ²MRC Functional Genetics Unit, Department of Human Anatomy & Genetics, University of Oxford, Oxford OX1 3QX

1 We report the cloning and expression of a novel *Caenorhabditis elegans* polypeptide, GLC-3, with high sequence identity to previously cloned L-glutamate-gated chloride channel subunits from nematodes and insects.

2 Expression of *glc-3* cRNA in *Xenopus* oocytes resulted in the formation of homo-oligomeric Lglutamate-gated chloride channels with robust and rapidly desensitizing currents, an EC₅₀ of 1.9 ± 0.03 mM and a Hill coefficient of 1.5 ± 0.1 . GABA, glycine, histamine and NMDA all failed to activate the GLC-3 homo-oligomer at concentrations of 1 mM. The anthelminthic, ivermectin, directly and irreversibly activated the L-glutamate-gated channel with an EC₅₀ of $0.4\pm0.02 \mu$ M.

3 The GLC-3 channels were selective for chloride ions, as shown by the shift in the reversal potential for L-glutamate-gated currents after the reduction of external Cl^- from 107.6 to 62.5 mM.

4 Picrotoxinin failed to inhibit L-glutamate agonist responses at concentrations up to 1 mM. The polycyclic dinitrile, 3,3-bis-trifluoromethyl-bicyclo[2,2,1]heptane-2,2-dicarbonitrile (BIDN), completely blocked L-glutamate-induced chloride currents recorded from oocytes expressing GLC-3 with an IC₅₀ of $0.2\pm0.07 \ \mu$ M. The phenylpyrazole insecticide, fipronil, reversibly inhibited L-glutamate-gated currents recorded from the GLC-3 receptor with an IC₅₀ of $11.5\pm0.11 \ \mu$ M.

5 In this study, we detail the unusual antagonist pharmacology of a new GluCl subunit from *C. elegans.* Unlike all other native and recombinant nematode GluCl reported to date, the GLC-3 receptor is insensitive to picrotoxinin, but is sensitive to two other channel blockers, BIDN and fipronil. Further study of this receptor may provide insights into the molecular basis of non-competitive antagonism by these compounds.

British Journal of Pharmacology (2001) 132, 1247-1254

Keywords: Glutamate-gated chloride channel; Caenorhabditis elegans; ivermectin; BIDN; fipronil; picrotoxinin

Abbreviations: BIDN, 3,3-bis-trifluoromethyl-bicyclo[2,2,1]heptane-2,2-dicarbonitrile; DMSO, dimethyl sulphoxide; EBOB, 1-(4-ethynylphenyl)-4-[2,3H₂]propyl-2,6,7-trioxabicyclo[2,2,2]octane; Fip, fipronil; GluCl, glutamate-gated chloride channel; HisCl, histamine-gated chloride channel; PKC, protein kinase C; PTX, picrotoxinin; SL, spliced leader; SOS, standard oocyte saline; TBPS, *t*-butylbicyclophosphorothionate

Introduction

The completion of the Caenorhabditis elegans genome sequence (C. elegans Sequencing Consortium, 1998) has permitted the first prediction of the total number of ionotropic receptor subunits present within an organism. The sequence predicts that the nematode genome encodes about 90 such subunits (Bargmann, 1998), including 37 ligand-gated anion channel subunits, most of which are of unknown function. The L-glutamate-gated chloride channels (GluCls) are an important group of ionotropic receptors, to date found only on invertebrate nerve and muscle cells (reviewed by Cleland, 1996). The GluCls are closely related to receptors for GABA and glycine that gate chloride channels and are presumed to possess a similar pentameric structure. The C. elegans GluCl subunits cloned to date share about 40% identity with glycine receptor subunits and 30-35%identity with mammalian GABAA and GABAC receptor

subunits at the amino-acid level. There is strong evidence that the GluCls are targeted by the avermectin/milbemycin family of endectocides and insecticides (Arena *et al.*, 1992; 1995; Cully *et al.*, 1994; 1996; Dent *et al.*, 2000), though it is not known whether all GluCls are sensitive to these compounds. The invertebrate GABA-gated chloride channels are also targeted by insecticides such as the phenylpyrazole, fipronil, providing further evidence of the importance of the ligandgated anion channel superfamily in pest control.

Many recombinant GluCls described to date are blocked by the convulsant picrotoxinin (PTX), a plant derived toxin that blocks vertebrate and invertebrate native and recombinant GABA- and glycine-gated anion channels (Cull-Candy, 1976; Olsen & Tobin, 1990; Pribilla *et al.*, 1992; Hosie *et al.*, 1997). A number of convulsants also act at insect GABAgated anion channels, including PTX, the picrodendrins (Hosie *et al.*, 1996), the bicyclic dinitrile BIDN (Rauh *et al.*, 1997; Hamon *et al.*, 1998) as well as fipronil (Cole *et al.*, 1993; Hosie *et al.*, 1995). The antagonist activity of these

^{*}Author for correspondence; E-mail: A.J.Wolstenholme@bath.ac.uk

compounds is thought to target the convulsant binding sites of the *Drosophila melanogaster* GABA-gated chloride channel subunit, RDL (Shirai *et al.*, 1995; Hosie *et al.*, 1997). Fipronil, PTX and BIDN antagonism of RDL are all affected by a mutation (A302S) in the channel-lining second transmembrane region, M2, (Hosie *et al.*, 1995; Shirai *et al.*, 1995) that makes the channel resistant to picrotoxinin and dieldrin (ffrench-Constant *et al.*, 1993; Hosie *et al.*, 1995). An equivalent mutation of the *C. elegans* GluC1 β subunit (A279T) reduces the sensitivity of this receptor to PTX by 10,000 fold (Etter *et al.*, 1999). BIDN and fipronil have not so far been tested on a nematode ligand-gated anion channel.

Searches of the *C. elegans* genome sequence revealed a predicted polypeptide, ZC317.3, with a high amino-acid identity to the cloned GluCl subunits. We report here the amplification and expression of the cDNA encoding this polypeptide together with an agonist and antagonist profile of the expressed receptor including the convulsant GABA_A antagonists, BIDN and fipronil. Based on the sequence of the polypeptide and functional expression data we conclude that this gene, designated *glc-3*, encodes a further GluCl subunit from *C. elegans*.

Methods

Cloning of ZC317.3 cDNA

The N2 strain of C. elegans was maintained on the OP50 strain of E. coli in Petri dishes. RNA was extracted from mixed stage worms using the TrizoleTM reagent (Life Technologies, Paisley, U.K.) and cDNA synthesized from total RNA using oligo- dT_{17} (in the initial experiments) or random hexamers (for full-length amplifications) as primers. Reagents used were from the Superscript system (Life Technologies). Amplification of the fulllength ZC317.3 cDNA was carried out in a 50 μ l reaction volume using specific oligonucleotide primers corresponding to the 5' (5'CTTGATGAGTCTCCGTTCACTTC3') and 3' (⁵CAATTTCATTTGGCTTCCGGTGCG³) ends of the predicted gene and 2.6 units of ExpandTM High Fidelity DNA polymerase (Boehringer, Lewes, U.K.). The PCR amplification consisted of a 2-min 'Hot Start' at 94°C, followed by 40 cycles of 30 s denaturation at 94°C, an annealing temperature of 55°C for 30 s and an extension time of 30 s at 72°C with a final extension step at 72°C for 5 min. The cDNA was subcloned into pGEM®-T Easy (Promega, Southampton, U.K.) for cRNA synthesis. DNA sequencing reactions were carried out by DNASHEF, Edinburgh, U.K. and analysed using the GCG package mounted on a Silicon Graphics Unix workstation.

Preparation of synthetic cRNA for oocyte injection

The recombinant plasmid containing the full-length *glc-3* cDNA was linearised at the 3' end of the insert. The linearised plasmid was diluted to a final concentration of 1 $\mu g \mu l^{-1}$ with RNAse free water. 15–35 μg of 7-methylguanosine capped cRNA was synthesized from 1 μg of DNA template using T7 RNA polymerase and a capped RNA transcription kit (mMessage mMachine, Ambion, Austin, TX, U.S.A.).

Oocyte preparation and injection

Ovarian tissue was surgically extracted from Xenopus laevis females anaesthetized using 0.2% (w v⁻¹) tricaine (3aminobenzoic acid ethyl ester, methane sulphonate salt), (Sigma Chemical Co., St Louis, U.S.A.), and the isolated ovarian lobes dissected into small clumps each containing approximately 50 oocytes. The follicular layers were defolliculated manually from the oocytes following a 5-10 min incubation with collagenase (Sigma type1A, 2 mg ml⁻¹) in a calcium-free version of standard oocyte saline (SOS); normal SOS is (mM) NaCl 100, KCl 2, CaCl₂ 1.8, MgCl₂ 1, HEPES 5 (pH 7.6). Reduced [Cl⁻] SOS contained 54.9 mM NaCl and 45.1 mM sodium gluconate instead of 100 mM NaCl; all other constituents were the same as normal SOS. Oocytes were then transferred to SOS supplemented with 2.5 mM sodium pyruvate, streptomycin (100 μ g ml⁻¹), penicillin (100 units ml⁻¹) and gentamycin (50 μ g ml⁻¹). All antibiotics were from Sigma.

Each oocyte was injected cytoplasmically (Drummond 'Nanoject' microinjector, Broomhall, PA, U.S.A.) with 50 nl of capped cRNA (1 ng nl⁻¹). Injected oocytes were placed at 17° C and allowed to incubate for 1-6 days with replacement of saline at 24 h intervals. The data were obtained from oocytes incubated for 3-6 days after injection.

Electrophysiological recordings

Membrane current measurements were made using a twoelectrode voltage-clamp amplifier OC-725C (Warner, Warner Instrument Corp, U.S.A.). Microelectrodes were pulled from borosilicate glass capillaries (Clark Electromedical, U.K.) on a microelectrode puller (Scientific and Research Instruments, Ltd., U.K.) to a resistance, when filled with 3 M KCl, of between 0.5 and 5 M Ω . Each oocyte was positioned in a Perspex-recording chamber and impaled with two microelectrodes. The bath was perfused with normal SOS, unless otherwise stated, supplied through a gravity-fed system at a rate of 5 ml min⁻¹. Oocytes were normally maintained at a holding potential of $E_h = -80$ mV and all membrane currents were recorded on a Gould BS-272 chart recorder.

Drug application protocol

Fipronil (Chemserv, U.S.A.) and BIDN (donated by DuPont Agricultural Products) were dissolved in DMSO $(<1\% v v^{-1}$ final concentration in saline) and ivermetin (Sigma) was dissolved in ethanol (<0.1% v v⁻¹ final concentration in saline); these solvent concentrations were shown to have no effect either on the responses of GluCl expressing or uninjected oocyte membranes when cells were clamped at $E_h = -80$ mV. A dose-dependent relationship for L-glutamate was generated by challenging the expressed receptor first with 3 mM applications of L-glutamate followed by increasing concentrations of agonist (10 μ M to 100 mM) at 5 min intervals, as a result of which agonist responses of constant amplitude were consistently observed. The response to each concentration of agonist was expressed as a percentage of the peak response (%Imax). The response to each concentration of ivermectin was obtained on individual oocytes and normalized to the current in response to 3 mM L-glutamate for that oocyte. For studies on fipronil and other antagonists, oocytes were incubated in different antagonist test concentrations for 2 min prior to application of 3 mM L-glutamate in the continued presence of the test concentration of the antagonist. The process was repeated with a higher concentration of the antagonist following a 3-5 min recovery period in normal SOS. The amplitude of the response to co-application of antagonist and L-glutamate was normalized to the values obtained in the presence of 3 mM L-glutamate in physiological saline.

Data were analysed using Graphpad prism (Graphpad Software) and presented as the mean \pm the standard error of the mean. Hill coefficients were calculated using the following equation.

$$\frac{I}{I_{\max}} = \frac{I_{\min}}{I_{\max}} + \frac{I_{\max} - I_{\min}}{[1 + 10^{(\log EC_{50} - [ag] * n_{H})}]} I_{\max}$$

This equation was used to fit a sigmoid curve of variable slope to the normalized data. I_{max} and I_{min} represent the maximal and minimal currents induced by a particular agonist. The EC₅₀ is the concentration of agonist necessary to elicit half the maximum response and n_H is the slope (Hill) coefficient.

Results

PCR amplification of the ZC317.3 cDNA

Our initial attempts to detect mRNA transcribed from the ZC317.3 gene used oligonucleotide primers designed to wellconserved portions of GluCl subunits in combination with generic 3' (oligo-dT) and 5' (SL1) sequences. These experiments suggested that the computer-predicted ends of the open reading frame were accurate, allowing us to synthesize oligonucleotides that included the predicted initiation and termination codons. Using these primers, PCR resulted in the amplification of an approximately 1400 bp cDNA. The cDNA was cloned into pGEM®-T Easy and sequenced: the sequence has been submitted to the EMBL database (Accession Number AJ243914). The ZC317.3 cDNA includes an open reading frame of 484 amino acids containing all the characteristics of invertebrate L-glutamate-gated chloride channel subunits (Figure 1). These features include a predicted signal peptide at the Nterminus and a long N-terminal extracellular domain that contains a characteristic 2nd pair of cysteine residues, in addition to the dicysteine loop (amino-acids 138 and 152 of the mature polypeptide; positions 218 and 232 on Figure 1), at amino-acids 199 and 210 of the predicted mature GLC-3

	1									1 00
GLC-3	MSLRSLLNIL	LIVAFWIVGG	NCD					ASSDTEIIKK	LLGKGYDWRV	RPPGINLTIP
GluCla	MATWIVGKLI	IASLILGIQA	QQARTKSQ	D	IFEDDNDNGT	TTLESLARLT	SPIHIPIEQP	QTSDSKILAH	LFTSGYDFRV	RPPTDN
GluCla2	MSTSFIRRLA	FVGLLLGVHA	YHSRPKSEEH	SPKHAASSSD	LFEDDDQS	TTLESIARLS	APAHVPIEQP	QTSDTEILEH	LLTRGYDHRV	RPPGEDGTIH
GBR-2B	MWHYRLTTIL	LIISIIHSIR.					AKR	KLKEQEIIQR	IL.KDYDWRV	RPRGMNATWP
Consensus								I	YD-RV	RP
10	0.1									200
GLC-3	GTHGAVIVYV	NMLIRSISKI	DDVNMEYSVQ	LTFREEWVDG	RLAYGFPGDS	TPDFLI	LTAG	QQIWMPDSFF	QNEKQAHKHD	IDKPNVLIRI
GluCla	GGPVVVSV	NMLLRTISKI	DVVNMEYSAQ	LTLRESWIDK	RLSYGVKGDG	QPDFVI	LTVG	HQIWMPDTFF	PNEKQAYKHT	IDKPNVLIRI
GluCla2	GGPVVVSV	NMLLRSISKI	DNVNMEYSVQ	LTFRESWVDK	RLSFGVKGDA	QPDFLI	LTAG	QEIWMPDSFF	QNENQAYKHM	IDKPNVLIRV
GBR-2B	DTGGPVLVTV	NIYLRSISKI	DDVNMEYSAQ	FTFREEWTDQ	RLAYERYEES	GDTEVPPFVV	LATSENADQS	QQIWMPDTFF	QNEKEARRHL	IDKPNVLIRI
Consensus	G-V-V-V	NR-ISKI	D-VNMEYS-Q	-T-RE-W-D-	RL	P-F	L	IWMPD-FF	-NEAH-	IDKPNVLIR-
										200
GLC-3	HEDGETLYSV	RISMULSCEM	HLOYYPMDVO	TCLIDLASYA	YTENDIEYBW	KKTDPVOLKK	GLHSSLPSFE	LNNVDTTLCT	SKTNTGTYSC	LETVLELERO
GluCla	HNDGTVLYSV	RISLVLSCPM	YLOYYPMDVO	OCSTDLASYA	YTTKDIEYLW	KEHSPLOLKV	GLSSSLPSFO	LTNTSTTYCT	SVTNTGIYSC	LRTTIOLKRE
GluCla2	HEDGTILYSV	RISLVLSCPM	HLOYYPMDVO	OCFIDLASYA	YTTKDIEYVW	KEETPVOLKA	GLSSSLPSFO	LTNTSTTYCT	SKTNTGSYSC	LETIIOLERO
GBR-2B	HKNGOILYSV	RLSLVLSCPM	SLEFYPLDRO	NCLIDLASYA	YTTODIKYEW	KEKKPIOOKD	GLRQSLPSFE	LQDVVTDYCT	SLTNTGEYSC	ARVVLRLRRE
Consensus	HGLYSV	R-S-VLSCPM	-LYP-D-Q	-C-IDLASYA	YTDI-Y~W	КР-Q-К-	GLSLPSF-	LTCT	S-TNTG-YSC	-RL-R-
								_	_	
30	01	M1		M	2			M3	•	400
30 GLC-3	FSYYLLQLYI	M1 PSTMLVIVSW	VSFWLDRGAV	M2 PARVTLGVTT	LLTMTTQASG	INAKLPPVSY	TKAIDVWIGA	M3 CLTFIFGALL	▼ EFAWVTYISS	400 RSFYKRNKNC
30 GLC-3 GluClα	01 FSYYLLQLYI FSFYLLQLYI	M1 PSTMLVIVSW PSCMLVIVSW	VSFWLDRGAV VSFWFDRTAI	M2 PARVTLGVTT PARVTLGVTT	LLTMTTQASG	INAKLPPVSY INSQLPPVSY	TKAIDVWIGA IKAIDVWIGA	M3 CLTFIFGALL CMTFIFCALL	EFAWVTYISS EFALVNHIAN	400 RSFYKRNKNC KQGVER.KAR
30 GLC-3 GluClα GluClα2 GluClα2)1 FSYYLLQLYI FSFYLLQLYI FSYYLLQLYI	M1 PSTMLVIVSW PSCMLVIVSW PSCMLVIVSW	VSFWLDRGAV VSFWFDRTAI VSFWIDRTAV	M2 PARVTLGVTT PARVTLGVTT PARVTLGVTT	LLTMTTQASG LLTMTAQSAG LLTMTTQSSG	INAKLPPVSY INSQLPPVSY INAKLPPVAY	TKAIDVWIGA IKAIDVWIGA IKAIDVWIGA	M3 CLTFIFGALL CMTFIFCALL CMTFIFCALL	EFAWVTYISS EFALVNHIAN EFAWVTYIAN	400 RSFYKRNKNC KQGVER.KAR KQDANK.RAR
36 GLC-3 GluClα GluClα2 GBR-2B Consensus)1 FSYYLLQLYI FSFYLLQLYI FSYYLLQLYI YSYYLIQLYI -S-YL-OLYI	M1 PSTMLVIVSW PSCMLVIVSW PSCMLVIVSW PCIMLVVVSW PMLV-VSW	VSFWLDRGAV VSFWFDRTAI VSFWIDRTAV VSFWLDKDAV	M2 PARVTLGVTT PARVTLGVTT PARVTLGVTT PARVSLGVTT PARVSLGVTT	LLTMTTQASG LLTMTTQSSG LLTMTTQSSG LLTMTTQASG LLTMTTQASG	INAKLPPVSY INSQLPPVSY INAKLPPVAY INTKLPPVSY INLPPV-Y	TKAIDVWIGA IKAIDVWIGA IKAIDVWIGA IKAVDVWIGV -KA-DVWIG-	M3 CLTFIFGALL CMTFIFCALL CMTFIFCALL CLAFIFGALL CFIF-ALL	EFAWVTYISS EFALVNHIAN EFAWVTYIAN EYAVVNYYGR E-A-V	400 RSFYKRNKNC KQGVER.KAR KQDANK.RAR KEFLRKEKKK
30 GLC-3 GluClα GluClα2 GBR-2B Consensus	01 FSYYLLQLYI FSFYLLQLYI FSYYLLQLYI YSYYLIQLYI -S-YL-QLYI	M1 PSTMLVIVSW PSCMLVIVSW PCIMLVVVSW PMLV-VSW	VSFWLDRGAV VSFWFDRTAI VSFWIDRTAV VSFWLDKDAV VSFW-DA-	M2 PARVTLGVTT PARVTLGVTT PARVTLGVTT PARVSLGVTT PARV-LGVTT	LLTMTTQASG LLTMTAQSAG LLTMTTQSSG LLTMTTQASG LLTMTTQG	INAKLPPVSY INSQLPPVSY INAKLPPVAY INTKLPPVSY INLPPV-Y	TKAIDVWIGA IKAIDVWIGA IKAIDVWIGA IKAVDVWIGV -KA-DVWIG-	M3 CLTFIFGALL CMTFIFCALL CMTFIFCALL CLAFIFGALL CFIF-ALL	EFAWVTYISS EFALVNHIAN EFAWVTYIAN EYAVVNYYGR E-A-V	400 RSFYKRNKNC KQGVER.KAR KQDANK.RAR KEFLRKEKKK
30 GLC-3 GluCla GluCla2 GBR-2B Consensus 402	D1 FSYYLLQLYI FSFYLLQLYI FSYYLLQLYI YSYYLIQLYI -S-YL-QLYI	M1 PSTMLVIVSW PSCMLVIVSW PSCMLVIVSW PCIMLVVVSW PMLV-VSW	VSFWLDRGAV VSFWFDRTAI VSFWIDRTAV VSFWLDKDAV VSFW-DA-	M2 PARVTLGVTT PARVTLGVTT PARVTLGVTT PARVSLGVTT PARV-LGVTT	2 LLTMTTQASG LLTMTTQSSG LLTMTTQASG LLTMTTQASG LLTMT-QG	INAKLPPVSY INSQLPPVSY INAKLPPVAY INTKLPPVSY INLPPV-Y	TKAIDVWIGA IKAIDVWIGA IKAIDVWIGA IKAVDVWIGV -KA-DVWIG-	M3 CLTFIFGALL CMTFIFCALL CLAFIFGALL CFIF-ALL	EFAWVTYISS EFALVNHIAN EFAWVTYIAN EXAVVNYYGR E-A-V	400 RSFYKRNKNC KQGVER.KAR KQDANK.RAR KEFLRKEKKK 500
30 GLC-3 GluCla GluCla2 GBR-2B Consensus 400 GLC-3	D1 FSYYLLQLYI FSFYLLQLYI FSYYLLQLYI FSYYLLQLYI YSYYLIQLYI -S-YL-QLYI SSRNSLLIET	M1 PSTMLVIVSW PSCMLVIVSW PSCMLVIVSW PCIMLVVVSW PMLV-VSW KQALIIPNTV	VSFWLDRGAV VSFWFDRTAI VSFWIDRTAV VSFWLDKDAV VSFW-DA- VAQFPEHPEE	M2 <u>PARVTLGVTT</u> <u>PARVTLGVTT</u> <u>PARVTLGVTT</u> <u>PARVSLGVTT</u> <u>PARV-LGVTT</u> <u>VEMGLAQAPD</u>	2 LLTMTTQASG LLTMTTQSSG LLTMTTQSSG LLTMTTQASG LLTMT-QG VWIRQSGNGK	INAKLPPVSY INSQLPPVSY INAKLPPVAY INTKLPPVSY INLPPV-Y TVSRVNGHIN	TK <u>AIDVWIGA</u> IK <u>AIDVWIGA</u> IK <u>AIDVWIGA</u> IK <u>AVDVWIGV</u> -KA-DVWIG- HNNDEAAELI	M3 CLTFIFGALL CMTFIFCALL CLAFIFGALL CFIF-ALL IFDAKHKNRR	EFAWVTYISS EFALVNHIAN EFAWVTYIAN EVAVVNYYGR E-A-V FVWWTNFRNI	400 RSFYKRNKNC KQGVER.KAR KQDANK.RAR KEFLRKEKKK
34 GLC-3 GluCla GluCla2 GBR-2B Consensus 400 GLC-3 GluCla	D1 FSYYLLQLYI FSFYLLQLYI FSYYLLQLYI FSYYLLQLYI YSYYLIQLYI -S-YL-QLYI SSRNSLLIET TEREKAEIPL	M1 PSTMLVIVSW PSCMLVIVSW PSCMLVIVSW PCIMLVVVSW PMLV-VSW KQALIIPNTV LQNLHNDV	VSFWLDRGAV VSFWFDRTAI VSFWIDRTAV VSFWLDKDAV VSFW-DA- VAQFPEHPEE PTKVFNQEEK	M2 PARVTLGVTT PARVTLGVTT PARVTLGVTT PARVSLGVTT PARV-LGVTT VEMGLAQAPD VRTVPLNRRQ	2 LLTMTTQASG LLTMTTQSSG LLTMTTQSSG LLTMTTQASG LLTMTTQASG VWIRQSGNGK M	INAKLPPVSY INSQLPPVSY INAKLPPVAY INTKLPPVSY INLPPV-Y TVSRVNGHIN	TK <u>AIDVWIGA</u> IK <u>AIDVWIGA</u> IK <u>AIDVWIGA</u> IK <u>AVDVWIGV</u> -KA-DVWIG- HNNDEAAELI	M3 CLTFIFGALL CMTFIFCALL CLAFIFGALL CFIF-ALL IFDAKHKNRR	EFAWVTYISS EFALVNHIAN EFAWVTYIAN EVAVVNYYGR E-A-V FVWWTNFRNI NSFLNL	400 RSFYKRNKNC KQGVER.KAR KQDANK.RAR KEFLRKEKKK 500 RLIRWIRNRL LETKTEWN
30 GLC-3 GluCla GluCla2 GBR-2B Consensus 400 GLC-3 GLC-3 GluCla GluCla2	D1 FSYYLLQLYI FSYYLLQLYI FSYYLLQLYI TSYYLIQLYI -S-YL-QLYI SSRNSLLIET TEREKAEIPL TEREKAEIPF	M1 PSTMLVIVSW PSCMLVIVSW PCMLVIVSW PCIMLVVVSW PMLV-VSW KQALIIPNTV LQNLHNDV LQNSHNDVWV	VSFWLDRGAV VSFWFDRTAI VSFWLDRTAV VSFWLDKDAV VSFW-DA- VAQFPEHPEE PTKVFNQEEK PREVAEQERE	M2 PARVTLGVTT PARVTLGVTT PARVTLGVTT PARVSLGVTT PARV-LGVTT VEMGLAQAPD VRTVPLNRRQ VMTVRMNRRQ	2 LLTMTTQASG LLTMTTQSSG LLTMTTQSSG LLTMTTQASG LLTMT-QG VWIRQSGNGK M T	INAKLPPVSY INSQLPPVSY INAKLPPVAY INTKLPPVSY INLPPV-Y TVSRVNGHIN	TK <u>AIDVWIGA</u> IK <u>AIDVWIGA</u> IKA <u>IDVWIGA</u> IKA <u>VDVWIG</u> -KA-DVWIG- HNNDEAAELI	M3 CLTFIFGALL CMTFIFCALL CLAFIFGALL CLAFIFGALL CFIF-ALL IFDAKHKNRR	EFAWVTYISS EFALVNHIAN EFAWVTYIAN EYAVVNYYGR E-A-V FVWWTNFRNI NSFLNL NSFLNL	400 RSFYKRNKNC KQGVER.KAR KQDANK.RAR KEFLRKEKKK
30 GLC-3 GluCla GLuCla2 GBR-2B Consensus GLC-3 GluCla GLUCla2 GBR-2B	D1 FSYYLLQLYI FSFYLLQLYI FSYYLLQLYI YSYYLIQLYI -S-YL-QLYI SSRNSLLIET TEREKAEIPL TEREKAEIPL KTR	M1 <u>PSTMLVIVSW</u> <u>PSCMLVIVSW</u> <u>PCIMLVVVSW</u> <u>P-MLV-VSW</u> KQALIIPNTV LQNLHNDV LQNSHNDVWV IDDCV	VSFWLDRGAV VSFWFDRTAI VSFWLDRTAV VSFWLDKDAV VSFWDD-A- VAQFPEHPEE PTKVFNQEEK PREVAEQERE CP	M2 PARVTLGVTT PARVTLGVTT PARVTLGVTT PARV-LGVTT VEMGLAQAPD VRTVPLNRQ VMTVRMRRQ SDRPP	2 LLTMTTQASG LLTMTTQSSG LLTMTTQSSG LLTMTTQSSG LLTMT-QG VWIRQSGNGK M LRLDLSA	INAKLPPVSY INSQLPPVSY INALPPVSY INTKLPPVSY IN-LPPV-Y TVSRVNGHIN	TKAIDVWIGA IKAIDVWIGA IKAIDVWIGA IKAVDVWIGV -KA-DVWIG- HNNDEAAELI	M3 CLTFIFGALL CMTFIFCALL CLAFIFGALL CFIF-ALL IFDAKHKNRR	EFAWVTYISS EFALVNHIAN EFAWVTYIAN EYAVVNYYGR E-A-V FVWWTNFRNI NSFINL NSVWKW YRSVKRL	400 RSFYKRNKNC KQGVER.KAR KQDANK.RAR KEFLRKEKKK 500 RLIRWIRNRL LETKTEWN. IKTKTEWN. PIIKRISEIL
34 GLC-3 GluClα GluClα2 GBR-2B Consensus GLC-3 GluClα GluClα2 GBR-2B Consensus	D1 FSYYLLQLYI FSFYLLQLYI FSYYLLQLYI YSYYLIQLYI SSRNSLLIET TEREKAELPF TEREKAELPF TEREKAELPF TEREKAELPF TEREKAELPF	M1 PSTMLVIVSW PSCMLVIVSW PCIMLVVVSW PMLV-VSW KQALIIPNTV LQNLHND.V LQNSHNDVWV V	VSFWLDRGAV VSFWLDRDATAV VSFWLDRDAV VSFW-DA- VAQFPEHPEE PTKVFNQEEK PREVABQERE CP	M2 PARVTLGVTT PARVTLGVTT PARVSLGVTT PARV-LGVTT VEMGLAQAPD VRTVPLNRRQ VMTVRMNRRQ	2 LLTMTTQASG LLTMTTQSAG LLTMTTQSSG LLTMTTQASG LLTMT-QG VWIRQSGNGK M T	INAKLPPVSY INSQLPPVSY INTKLPPVAY INTKLPPVSY INLPPV-Y TVSRVNGHIN	TKAIDVWIGA IKAIDVWIGA IKAIDVWIGA IKAVDVWIGV -KA-DVWIG- HNNDEAAELI	M3 CLTFIFGALL CMTFIFCALL CLAFIFGALL C-FIF-ALL IFDAKHKNRR	EFAWVTYISS EFALVMHIAN EFAWVTYIAN EYAVVNYGR E-A-V FVWWTNFRNI NSFURL NSVMKW YRSVKRL	400 RSFYKRNKNC KQGVER.KAR KQDANK.RAR KEFLRKEKKK
34 GLC-3 GluCla GluCla2 GBR-2B Consensus 400 GLC-3 GluCla GluCla2 GBR-2B Consensus	D1 FSYYLLQLYI FSFYLLQLYI FSYYLLQLYI YSYYLIQLYI SSRNSLLIET TEREKAELPF TEREKAELPF TEREKAELPF TEREKAELPT D1	M1 PSTMLVIVSW PSCMLVIVSW PCIMLVVVSW PMLV-VSW KQALIIPNTV LQNSHNDVVV LQNSHNDVVV V	VSFWLDRGAV VSFWLDRTAV VSFWLDRTAV VSFWLDRTAV VSFWLDRDAV VSFW-DA- VAQFPEHPEE PTKVFNQEEK PREVAEQERE CP M4	M2 PARVTLGVTT PARVTLGVTT PARVSLGVTT PARVSLGVTT PARVSLGVTT VEMGLAQAPD VRTVPLNRRQ VMTVPLNRRQ VMTVPLNRRQ	2 LLTMTTQASG LLTMTTQSSG LLTMTTQSSG LLTMTTQASG LLTMT-QA-G WWIRQSGNGK M T LRLDLSA	INAKLPPVSY INSQLPPVSY INTKLPPVAY INTKLPPVSY INLPPV-Y TVSRVNGHIN	TKAIDVWIGA IKAIDVWIGA IKAIDVWIGA IKAVDVWIGA -KA-DVWIG- HNNDEAAELI	M3 CLTFIFGALL CMTFIFCALL CLAFIFGALL C-FIF-ALL IFDAKHKNRR	EFAWVTYISS EFALVMHIAN EYAVVNYGR E-A-V FVWWTNFRNI NSFLNL NSVWKW YSVKKW	400 RSFYKRNKNC KQGVER.KAR KQDANK.RAR KEFLRKEKKK
34 GLC-3 GluCla2 GBR-2B Consensus GLC-3 GluCla2 GBR-2B Consensus 51 GLC-3	01 FSYYLLQLYI FSFYLLQLYI FSYYLLQLYI YSYYLIQLYI SSRNSLLIET TEREKAELPE KTR -R 01 NVD.DNAKRA	M1 PSTMLVIVSW PSTMLVIVSW PSCMLVIVSW P-MLV-VSW P-MLV-VSW KQALIIPNTV LQNLHNDV LQNSHNDVWV IDDCV DLISRVLFPT	VSFWLDRGAV VSFWTDRTAV VSFWLDRTAV VSFWLDRDAV VSFWLDRDAV VSFW-DA- VAQFPEHPEE PTKVFNQEEK PREVAEQERE CP M4 LFVCFNFVYW	M2 PARVTLGVTT PARVTLGVTT PARVSLGVTT PARVSLGVTT PARV-LGVTT VEMGLAQAPD VRTVPLNRRQ VMTVRMNRRQ SDRPP	2 <u>LLTMTTQASG</u> <u>LLTMTQSAG</u> <u>LLTMTQSG</u> <u>LLTMTQASG</u> <u>LLTMTQASG</u> <u>LLTMTQASG</u> <u>LLTMTQASG</u> <u>LLTMTQASG</u> <u>LLTMTQASG</u> <u>LLTMTQASG</u> <u>LTMTQASG</u> <u>LTMTQASG</u> <u>LTMTQASG</u> <u>LLTMTQASG</u> <u>LLTMTQASG</u> <u>LLTMTQASG</u> <u>LTMTQASG</u> <u>LTMTQASG</u> <u>LTMTQASG</u> <u>LLTMTQASG</u> <u>LLTMTQASG</u> <u>LLTMTQASG</u> <u>LLTMTQASG</u> <u>LTMTQASG</u> <u>LLTMTQASG</u> <u>LLTMTQASG</u> <u>LLTMTQASG</u> <u>LLTMTQASG</u> <u>LLTMTQASG</u> <u>LLTMTQASG</u> <u>LLTMTQASG</u> <u>LLTMTQASG</u> <u>LLTMTQASG</u> <u>LLTMTQASG</u> <u>LLTMTQASG</u> <u>LLTMTQASG</u> <u>LLTMTQASG</u> <u>LLTMTQASG</u> <u>LLTMTQASG</u> <u>LLTMTQASG</u> <u>LLTMTQASG</u> <u>LLTMTQASG</u> <u>LLTMTQASG</u> <u>LLTMTQASG</u> <u>LLTMTQASG</u> <u>LLTMTQASG</u> <u>LLTMTQASG</u> <u>LLTMTQASG</u> <u>LLTMTQASG</u> <u>LLTMTQASG</u> <u>LLTMTQASG</u> <u>LLTMTQASG</u> <u>LLTMTQASG</u> <u>LLTMTQASG</u> <u>LTMTQASG</u> <u>LLTMTQASG</u> <u>LLTMTQASG</u> <u>LTMTQASG</u> <u>LLTMTQASG</u> <u>LTMTQASG</u> <u>LTMTQASG</u> <u>LLTMTQASG</u> <u>LLTMTQASG</u> <u>LLTMTQASG</u> <u>LLTMTQASG</u> <u>LLTMTQASG</u> <u>LLTMTQASG</u> <u>LLTMTQASG</u> <u>LLTMTQASG</u> <u>LLTMTQASG</u> <u>LLTMTQASG</u> <u>LLTMTQASG</u> <u>LLTMTQASG</u> <u>LLTMTQASG</u> <u>LLTMTQASG</u> <u>LLTMTQASG</u> <u>LLTMTQASG</u> <u>LLTMTQASG</u> <u>LLTMTQASG</u> <u>LLTMTQASG</u> <u>LLTMTQASG</u> <u>LLTMTQASG</u> <u>LLTMTQASG</u> <u>LLTMTQASG</u> <u>LLTMTQASG</u> <u>LLTMTQASG</u> <u>LLTMTQASG</u> <u>LLTMTQASG</u> <u>LLTMTQASG</u> <u>LLTMTQASG</u> <u>LLTMT</u> <u>LTMTX</u> <u>LLTLS</u> <u>LLTMTX</u> <u>LTMTQASG</u> <u>LTMTQASG</u> <u>LTMTQASG</u> <u>LTMTQASG</u> <u>LTMTQASG</u> <u>LTMTX</u> <u>LTMTQASG</u> <u>LTMTQASG</u> <u>LTMTQASG</u> <u>LTMTX</u> <u>LTMTQASG</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u>LTMTX</u> <u></u>	INAKLPPVSY INSQLPPVSY INAKLPPVAY INTKLPPVSY IN-LPPV-Y TVSRVNGHIN	TKAIDVWIGA IKAIDVWIGA IKAIDVWIGA IKAVDVWIGO -KA-DVWIG- HNNDEAAELI 	M3 CLTFIFGALL CMTFIFCALL CLTFIFCALL CLTFIFCALL CFIF-ALL IFDAKHKNRR	EFAWVTYISS EFALVMHIAN EFAWVTYIAN EYAVVNYGR E-A-V FVWWTNFRNI NSFINL NSVWKW YRSVKRL	400 RSFYKRNKNC KQGVER.KAR KQDANK.RAR KEFLRKEKKK
34 GLC-3 GluCla2 GBR-2B Consensus 400 GLC-3 GluCla2 GBR-2B Consensus 50 GLC-3 GluCla2	D1 FSYYLLQLYI FSFYLLQLYI FSYYLLQLYI YSYYLLQLYI YSYYLLQLYI YSYYLLQLYI SSRNSLLIET TEREKAEIPL TEREKAEIPE KTR -R D1 NVD. DNAKRA DISKRY	M1 PSTMLVIVSW PSCMLVIVSW PSCMLVIVSW PCIMLVVVSW P-MLV-VSW KQALIIPNTV LQNLHND.V LQNSHNDVWV IDDCV DLISRVLFPT DLISRALFPY	VSFWLDRGAV VSFWLDRGAV VSFWLDRTAV VSFWLDRDAV VSFWLDRDAV VSFWLDRDAV VSFWLDRDAV VSFWLDRDAV VSFWLDRDAV VSFWLDRDAV VSFWLDRDAV VSFWLDRDAV VSFWLDRGAV VSFWLDGAV VSFWLDV	M2 PARVTLGVTT PARVLGVTT PARVSLGVTT PARVSLGVTT PARVSLGVTT VEMGLAQAPD VRTVPLNRRQ VMTVRMNRQ SDRPP SDRPP TKYSQYHAPE SRFGOONVLF	2 LLTMTTQASG LLTMTTQSAG LLTMTTQSSG LLTMTTQASG LLTMTTQASG LLTMT-QG VWIRQSGNGK M LRLDLSA 542 AK	INAKLPPVSY INSCLPPVSY INAKLPPVSY INTKLPPVSY IN-LPPV-Y TVSRVNGHIN	TKAIDVWIGA IKAIDVWIGA IKAIDVWIGA IKAVDVWIGY -KA-DVWIG- HNNDEAAELI 	M3 CLTFIFGALL CMTFIFGALL CLAFIFGALL CFIF-ALL IFDAKHKNRR 	EFAWUTYISS EFALUNHIAN EFAWUTYIAN EPAWUTYIAN E-A-V FVWWTNFRNI NSFLNL NSVKKW YRSVKRL 	400 RSFYKRNKNC KQGVER.KAR KQDANK.RAR KEFLRKEKKK
34 GLC-3 GluCla2 GBR-2B Consensus GLC-3 GluCla2 GBR-2B Consensus 51 GLC-3 GluCla2	D1 FSYYLLQLYI FSYYLLQLYI FSYYLLQLYI FSYYLLQLYI YSYYLLQLYI SSRNSLLET TEREKAEIPL TEREKAEIPL TEREKAEIPL TEREKAEIPL NVD. DNAKRA DISKRV DISKRV	M1 PSTMLVIVSW PSCMLVIVSW PCMLVVVSW PCMLVVVSW PMLV-VSW KQALIIPNTV LQNLHND.V LQNSHNDVWV IDDCV DLISRVLFPT DLISRVLFPT DLISRVFPV	VSFWLDRGAV VSFWLDRDATAI VSFWLDRDAV VSFWLDRDAV VSFW-DA- VAQFPEHPEE PTKVFNQEEK PREVABQERE CP M4 LFVCFNFVYW LFFVCFNFVYW LFFVFNILYW	M2 PARVTLGVTT PARVTLGVTT PARVSLGVTT PARVSLGVTT PARVSLGVTT VEMGLAQAPD VRTVPLNRRQ VMTVRMNRRQ SDRPP 	2 LLTMTTQASG LLTMTTQSAG LLTMTTQSSG LLTMTTQASG LLTMTTQASG LLTMTTQASG LLTMTTQASG LLTMTTQASG LLTMTTQASG LLTMTTQASG LLTMTTQASG LLTMTTQASG LLTMTTQASG LLTMTTQASG LLTMTTQASG LLTMTTQASG LLTMTTQASG LLTMTQASG ST ST ST ST ST ST ST ST ST ST	INAKLPPVSY INSCLPPVSY INAKLPPVSY INTKLPPVSY INLPPV-Y TVSRVNGHIN	TKAIDVWIGA IKAIDVWIGA IKAIDVWIGA IKAVDVWIGV -KA-DVWIG- HNNDEAAELI 	M3 CLTFIFGALL CMTFIFGALL CMTFIFGALL C-FIF-ALL IFDAKHKNRR 	EFAWVTYISS EFALVMHIAN EFAWTYIAN EYAVVNYGR E-A-V FVWWTNFRNI NSFLNL NSFLNL NSVKK YRSVKRL 	400 RSFYKRNKNC KQGVER.KAR KQDANK.RAR KEFLRKEKKK
34 GLC-3 GluCla2 GBR-2B Consensus GLC-3 GluCla2 GBR-2B Consensus 51 GLC-3 GluCla2 GBR-2B Consensus	D1 FSYYLLQLYI FSYYLLQLYI FSYYLLQLYI FSYYLLQLYI YSYYLIQLYI SSRNSLLIET TEREKAEIPL TEREKAEIPE KTR -R D1 NVD. DNAKRA DISKRV DISKRV STNIDISRV	M1 PSTMLVIVSW PSCMLVIVSW PCMLVVVSW P-MLV-VSW KQALIIPNTV LQNLHND.V LQNSHNDVWV V DLISRVLFPT DLISRALFPV DLISRVMFPV DLISRVMFPV DLISRVMFPY	VSFWLDRGAV VSFWLDRDAU VSFWLDRDAV VSFWLDRDAV VSFW-DA- VAQFPEHPEE PTKVFNQEEK PREVAEQERE CP M4 LFVCFNFVYW LFVCFNFVYW LFVFNILYW LFLFFNISYW	M2 PARVILGVTT PARVILGVTT PARVILGVTT PARV-LGVTT VEMGLAQAPD VRTVPLNRRQ VMTVRMNRQ MTVRMNRQ SDRPP TKYSQYHAPE SRFGQQNVLF THYGQYGVAI	2 LLTMTTQASG LLTMTTQASG LLTMTTQASG LLTMTTQASG LLTMTTQASG LLTMT-QG VWIRQSGNGK M	INAKLPPVSY INSQLPPVSY INTKLPPVAY INTKLPPVSY INLPPV-Y TVSRVNGHIN	TKAIDVWIGA IKAIDVWIGA IKAIDVWIGA IKAVDVWIGV -KA-DVWIG- HNNDEAAELI 	M3 CLTFIFGALL CMTFIFGALL CMTFIFGALL C-FIF-ALL IFDAKHKNRR 	EFAWVTYISS EFALVMHIAN EFAWVTYIAN EYAVVNYGR E-A-V FVWWTNFRNI NSFLNL NSFLNL NSVMKW YRSVKRL 	400 RSFYKRNKNC KQGVER.KAR KGDANK.RAR KEFLRKEKKK

Figure 1 Alignment of the amino acid sequence (single-letter code) of the *C. elegans* GLC-3 subunit with the GluCl α (Cully *et al.*, 1994), GluCl α 2 (Dent *et al.*, 1997; Vassilatis *et al.*, 1997) and GBR-2B (Laughton *et al.*, 1997) receptor subunits. The amino acid sequences were aligned using the computer program PILEUP. Where the amino acids are identical in all four sequences a consensus is shown along the bottom of the alignment; an absence of identity is indicated by a dash. The putative signal peptides are shown in italics and the transmembrane regions (M1–4) are underlined. For the GLC-3 sequence only the N-linked glycosylation site, the four cysteine residues in the extracellular domain and the consensus sites for phosphorylation by PKC in the intracellular loop are shown. Dots indicate gaps in the alignment.

polypeptide (positions 279 and 290 on the alignment shown in Figure 1), that distinguishes the L-glutamate- and glycinegated chloride channels from the ionotropic GABA receptors. A candidate site for N-linked glycosylation is located in the extracellular domain at residue 26 of the mature polypeptide. The extracellular domain is followed by four hydrophobic regions (M1–M4) that are predicted to cross the plasma membrane. Comparison of the cDNA sequence with the genomic sequence and with the amino-acid sequence predicted by Genefinder revealed that one of the intron/exon boundaries was not as predicted, resulting in a longer intracellular loop between M3 and M4. This loop contains two consensus sites for phosphorylation by protein kinase C.

When used to search the protein sequence databases, ZC317.3 exhibited greater than 50% amino-acid sequence identity to several invertebrate GluCl subunits (Table 1). A tree illustrating the relationship between the *C. elegans* and *Drosophila* GluCl subunits is shown in Figure 2 and an alignment of the GluCl α -like subunits is shown in Figure 1. The *C. elegans* ZC317.3 gene is therefore designated *glc-3* and the subunit it encodes GLC-3. GLC-3 appears to be most closely related to the previously characterized GluCl α and - α 2 subunits. It is noteworthy that neither the N-linked glycosylation site nor the protein kinase C sites are

Table 1 Amino acid identities of GLC-3 with other C.elegansGluCl subunits.Accession numbers and bibliographic data are given in Figures 1 and 2

Subunit	% identity
GluCla	60
GluCla2S	66
GBR-2B	58
GluClβ	50
C27H5.8	40
DmGluCl	50

conserved between GLC-3 and the other *C. elegans* α subunits, though a glycosylation site is present at a homologous position on the GBR-2 (GluCl α 3) subunits (Laughton *et al.*, 1997). Compared to GluCl α and α 2, GLC-3 is truncated by about 30 amino acids at the N-terminus, producing an extracellular domain similar in size to GBR-2, and has a slightly longer intracellular loop than any of the other GluCl subunits.

A functional homomeric GluCl is expressed in Xenopus oocytes injected with glc-3 cRNA

Xenopus oocytes injected with in vitro-transcribed cRNA encoding the GLC-3 polypeptide responded to L-glutamate, yielding robust, dose-dependent inward currents (at a holding potential of $E_h = -80$ mV) (Figure 3a, b). GABA, histamine, glycine and the excitatory L-glutamate-gated channel agonist, NMDA, at concentrations of 1 mM (n=5tests each on a different oocyte for each ligand) all failed to activate the expressed receptor (data not shown). Control oocytes injected with the same volume of deionized water and non-injected oocytes failed to respond to L-glutamate when it was applied at concentrations from 3 μ M to 10 mM (n=6). The conformationally constrained L-glutamate analogue, ibotenic acid, activated the GLC-3 receptor at 1 mM, but produced non-desensitizing currents of a smaller amplitude and slower onset than L-glutamate (Figure 3a). The EC₅₀ and Hill coefficients for L-glutamate were 1.90 ± 0.03 mM and 1.5 ± 0.10 , (n=6) respectively (Figure 3b). L-glutamate evoked-currents (Iglu) showed a rapid onset and desensitized rapidly in the presence of the neurotransmitter. Reduction of the external NaCl concentration to 54.9 mM and its partial replacement by 45.1 mM monosodium gluconate shifted the reversal potential (E_{rev}) for Lglutamate-sensitive currents from -16.6 to -7.3 mV, which is in the appropriate direction predicted by the Nernst equation (Figure 3c, n=4).



Figure 2 Unrooted neighbour-joining tree of the amino-acid sequences of invertebrate Glu-Cl subunits. Sequences were aligned using Pileup and the tree calculated using Phylip and 100 bootstrap replicates. All the sequences shown are from *C. elegans* except *Dm*GluCl, which is the *Drosophila* GluCl described by Cully *et al.* (1996). Accession numbers: GluCl α U14524, GluCl α AJ000537, GluCl β U14525, GBR-2A U40573, GBR-2B U41113, *Dm*GluCl U58776, C27H5.8 U14635.

Actions of ivermectin on the expressed homomeric GLC-3 receptor

Oocytes expressing the GLC-3 protein exhibited slowly activating, irreversible, inward IVM-sensitive currents which were dose-dependent (Figure 4a). No such responses were observed in either uninjected oocytes or in oocytes injected with distilled water. Large, non-desensitizing, IVM-sensitive inward currents were observed following the application of 0.1 and 1 μ M IVM, whereas 0.01 μ M IVM failed to gate the channel (n=3). Dose-dependent currents elicited by ivermectin (Figure 4b; n=6) generated an EC₅₀ value of 0.4 \pm 0.02 μ M and a Hill coefficient of 4.9 \pm 0.84. We observed no potentiation of sub-maximal L-glutamate-gated currents in the presence of low (0.01 μ M) concentrations of ivermectin (data not shown).

Actions of convulsant antagonists on GLC-3 receptors

Picrotoxinin (PTX) is a potent antagonist of many native and recombinant vertebrate and invertebrate GABA-gated chloride channels (Cull-Candy, 1976; Olsen & Tobin, 1990; Becker, 1992; Pribilla *et al.*, 1992), and of some native and



Figure 4 Ivermectin-induced dose-dependent inward currents. (a) Robust inward currents recorded in a single *Xenopus* oocyte expressing GLC-3 protein, voltage clamped at -80 mV. Horizontal bars above the trace indicate consecutive 30 s applications of IVM at increasing concentrations. (b) Dose-dependent ivermectin response curve. Each data point represents the ivermectin response from a minimum of six individual oocytes. The response is shown as the mean from at least six oocytes±standard error of the mean (s.e.mean), normalized to the response to 3 mM L-glutamate in each oocyte.



Figure 3 Responses to L-glutamate and other candidate ligands of Xenopus oocytes expressing GLC-3. Two-electrode voltage clamp electrophysiology was used to record L-glutamate activated inward currents in oocytes injected with in vitro-synthesized glc-3 RNA. (a) Inward currents recorded in the presence of 1 mM L-glutamate or 1 mM ibotenic acid, from oocytes voltage-clamped at -80 mV. Horizontal bars indicate the duration of agonist application and the downward deflection denotes an inward current. (b) L-glutamate concentration-response curves of oocytes injected with in vitro cRNA encoding the GLC-3 subunit and water-injected control oocytes clamped at -80 mV. Data were normalized to the maximum Lglutamate response seen with each oocyte and are shown as the standard error of the mean (s.e.mean) of \ge six oocytes taken from a minimum of two animals. The inset shows typical responses observed following the application of 3 μ M, 300 μ M and 8 mM L-glutamate. (c) Current-voltage relationship of the L-glutamate-induced currents (3 mM) in Xenopus oocytes pre-injected with cRNA encoding GLC-3 subunits in normal saline and reduced [Cl-] saline. Data were normalized to the response observed at a voltage clamp of +20 mVand each point is the mean of the responses seen in ≥ 3 oocytes \pm the standard error of mean.

recombinant GluCls (Arena et al., 1992; Cully et al., 1994; Cleland, 1996; Vassilatis et al., 1997; Etter et al., 1999). However, at concentrations of 0.01 to 1000 μ M, it failed to inhibit the robust L-glutamate (3 mM) agonist response in oocytes expressing the GLC-3 receptor (Figure 5, n=6). The bicyclic dinitrile convulsant, BIDN and the insecticide, fipronil (10 μ M), had no direct effect on either uninjected oocytes or oocytes injected with GLC-3 cRNA, all of which were clamped at $E_h = -80$ mV. Both BIDN and fipronil resulted in a dose-dependent suppression of the amplitude of the L-glutamate-gated chloride currents (n=5 for both)antagonists) (Figure 5b). The amplitude of the L-glutamate responses was restored after a 10 min wash in normal saline. For antagonist concentrations of 10 μ M and above recovery was slower and often incomplete. The estimated IC₅₀ for the co-application of BIDN and 3 mM L-glutamate was $0.2 \pm 0.07 \ \mu$ M and for fipronil the IC₅₀ was $11.5 \pm 0.11 \ \mu$ M (Figure 5b).

Discussion

Analysis of the genomic sequence of C. *elegans* strongly suggested that the ZC317.3 gene encoded a GluCl subunit. Our ability to amplify a cDNA derived from this gene by

RT-PCR methods shows that the gene is transcribed and thus it is very likely that the subunit polypeptide is expressed in the nematode. The amplified sequence indicates that the gene differs in its intron:exon structure from that predicted, but the 5' and 3' ends of the transcript appear to have been correctly predicted by the Genefinder programme. The polypeptide encoded by this clone exhibits the characteristic features of the 'cys-loop' receptor subunit family, with a long hydrophilic N-terminal region containing a 15 amino-acid dicysteine loop and four predicted membrane-spanning regions (M1-M4). The polypeptide also contains the second pair of cysteine residues in the extracellular domain that are typical of GluCl and glycine receptor subunits, as well as consensus sequences for one N-linked glycosylation and two phosphorylation sites. The sequence most closely resembles that of the C. elegans GluCla, GluCla2 and GBR-2 (GluCl α 3) subunits, though the level of identity between GLC-3 and the GluCl α subunits is rather lower (60-66%) than that between GluCl α and GluCl α 2 (76%) as illustrated in Figure 2. The overall significance of this may become clear once in vivo functions and subunit composition of the various GluCls have been established. The consensus PKC phosphorvlation sites found in the long intracellular loop of ZC317.3 are not conserved in any of the other GluCl subunits and the lack of additional basic residues close to the consensus



Figure 5 The GABA channel antagonists, picrotoxinin (PTX), fipronil (Fip) and BIDN were tested on 3 mM L-glutamate-elicited responses recorded from GLC-3 homo-oligomers. (a) For each antagonist, three responses are shown (Control) 3 mM L-glutamate, 3 mM L-glutamate in the presence of test antagonist, 3 mM L-glutamate recovery response after 3-5 min wash in normal saline. (b) Dose-response curves for the actions of fipronil, picrotoxinin and BIDN on the L-glutamate response of the GLC-3 receptor. Oocytes were incubated for 2 min in the candidate antagonist prior to co-application of L-glutamate and the test antagonist. The response 15 s after the co-application of L-glutamate plus antagonist was normalized to the response elicited from each oocyte after the application of 3 mM L-glutamate alone. Each point is the mean observation from a minimum of four oocytes.

phosphorylation sites may argue against any functional role for them *in vivo*.

The high level of sequence identity of the GLC-3 with the GluCla and GluCla2 subunits suggests that the novel polypeptide might have a similar function. When expressed in Xenopus oocytes, the functional properties of the receptor formed by this clone are indeed very similar to those described for the two previously cloned GluCla subunits in that they are activated by both L-glutamate and ivermectin. The EC₅₀ for L-glutamate of 1.9 ± 0.03 mM for the GLC-3 receptor was close to the reported values of 1.36 ± 0.05 mM for the GluCl α + β receptor (Cully *et al.*, 1994) and 2.0 ± 0.3 mM for the GluCla2 receptor (Dent *et al.*, 1997). Ibotenate was a weak agonist on the homomeric GLC-3 receptor, as reported for the GluCl α + β receptor (Cully *et al.*, 1994). The expressed channels appeared to be selective for Cl⁻ ions, as indicated by the shift in reversal potential for Lglutamate-gated current when the external sodium chloride was partially replaced by monosodium gluconate. The estimated Hill coefficient for L-glutamate was greater than 1, in agreement with all other expressed C. elegans GluCls (Cully et al., 1994; Dent et al., 1997; Vassilatis et al., 1997). An ability to irreversibly bind ivermectin, resulting in channel opening, may be diagnostic for α -like subunits of the GluCl, as the GluCl β subunit is not activated by these compounds (Cully et al., 1994), though Dent et al. (2000) have reported that one of the alternatively-spliced GluCla3 subunits does not form ivermectin- or glutamate-gated channels. Homomeric GLC-3 receptors are slowly and irreversibly activated by ivermectin in a dose-dependent manner similar to that described for GluCla2. Currents elicited by ivermectin (Figure 4b) generated an EC₅₀ value of $0.4 \pm 0.02 \ \mu M$ and a Hill coefficient of 4.91 ± 0.845 . The EC₅₀ for ivermeetin at the GLC-3 receptor is similar to those reported for ivermectin phosphate at the $\alpha 1$ and $\alpha 2$ subunits (0.14 and 0.11 μM respectively) (Cully et al., 1994; Vassilatis et al., 1997).

Experiments with non-competitive antagonists of ionotropic receptors containing chloride channels revealed some novel features of the homomeric GLC-3 receptor. The GLC-3 channels are insensitive to picrotoxinin at 1 mM, but are inhibited by BIDN and fipronil with IC₅₀s of 0.22 and 11 μ M respectively. This is the first report that any recombinant GluCl is sensitive to the actions of BIDN or a phenylpyrazole. These compounds are known to target GABA-gated chloride channels (Deng et al., 1993; Hosie et al., 1995; Rauh et al., 1997) and the new findings presented here indicate that GluCls and ionotropic GABA receptors show some similarities in their binding sites for certain convulsants. A naturally occurring mutation in the second membrane-spanning region (M2) of the Drosophila subunit RDL (A302S) confers both picrotoxinin and fipronil resistance (Pribilla et al., 1992; ffrench-Constant et al., 1993; Zhang et al., 1994; 1995; Gurley et al., 1995; Hosie et al., 1995; Wang et al., 1995). This mutation is predicted to lie deep in the GABA receptor pore (Olsen & Tobin, 1990; Smith & Olsen, 1995; Xu et al., 1995). However, the sequences of the M2 regions of the C. elegans GluCl subunits (Figure 1) are almost identical to each other, in particular the residue in M2 equivalent to A302 of RDL is a serine or threonine in all these subunits. This does not suggest any obvious reason for the observed differences in antagonist sensitivity between GLC-3 and the other GluCls. It is possible that residues outside the ion channel affect the antagonist

sensitivity and specificity of the GluCls. Lynch et al. (1995) showed that mutations at the extracellular end of the M2 of the mammalian glycine receptor α subunit, notably alterations in lysine-274, transformed picrotoxin from an allosteric competitive antagonist to an allosteric potentiator at low $(0.01-3 \ \mu M)$ concentrations and to a non-competitive antagonist at higher (>3 μ M) concentrations. Again, the sequence of this region of GLC-3, in particular the basic residue equivalent to K274, is conserved. [3H]-BIDN binding to insect membranes is displaced competitively by dieldrin but not by fipronil or PTX (Rauh et al., 1997). Fipronil is a noncompetitive antagonist of [35S]-TBPS and [3H]-EBOB binding to insect GABA receptors (Cole et al., 1993; Deng et al., 1993), unlike PTX (Bloomquist, 1993; Casida, 1993). Therefore it is likely that BIDN and fipronil bind to distinct sites from dieldrin, PTX and each other, even though the activity of all four compounds is affected by the same mutation (A302S) in the RDL channel. The interesting pharmacology observed for GLC-3 indicates that this and other C. elegans GluCls may prove to be valuable tools for studying the interactions of noncompetitive antagonists with ligand-gated chloride channels. In particular, it will be interesting to determine whether or not other native and other recombinant GluCls are sensitive to fipronil, BIDN and related compounds.

Very recently three novel ligand-gated chloride ion channels have been cloned from invertebrates; two histamine-gated chloride channel (HisCl) subunits from *Drosophila* and a 5HT-gated channel (MOD-1) from *C. elegans* (Zheng *et al.*, 2000; Ranganathan *et al.*, 2000). Though the histamine-gated channel subunits show close sequence similarity with the GluCls, the absence of any response to histamine by the GLC-3 receptor shows that this subunit is very unlikely to form part of a nematode HisCl. The sequence of MOD-1 is quite distinct from that of GLC-3 and the channel does not respond to L-glutamate or ivermectin (Ranganathan *et al.*, 2000) so GLC-3 is also unlikely to form part of a 5HT-gated channel, based on sequence and pharmacological differences.

It might be that GLC-3 is only a minor component of the ivermectin receptors found in *C. elegans*, since Vassilatis *et al.* (1997) concluded that the majority of [³H]-ivermectin binding sites present in membrane preparations could be accounted for by the GluCl α and GluCl α 2 subunits. Dent *et al.* (2000) showed that mutations in three genes (*glc-1, avr-14* and *avr-15*) resulted in a 4000-fold resistance to ivermectin and almost complete abolition (>97%) of high-affinity (<3 nM) ivermectin binding. Alternatively, GLC-3 might co-assemble with one or more of the other GluCl subunits to form a component of the ivermectin-binding sites. Detailed investigation of this latest member of the GluCl gene family using the advanced molecular genetic techniques available for *C. elegans* will enhance our overall understanding of chemical neurotransmission in the nematode nervous system.

We thank Dr Howard Baylis (Dept. of Zoology, University of Cambridge) for much practical help, constructive discussion and a donation of *C. elegans* cDNA, and Dr Nigel Mongan (Babraham Institute) for helpful discussion. L. Horoszok was supported by a BBSRC Research Studentship and by a project grant (061043) from the Wellcome Trust. V. Raymond was supported by grants to D.B. Sattelle from Merck and Co, U.S.A. and the Medical Research Council.

References

- ARENA, J.P., LIU, K.K., PARESS, P.S. & CULLY, D.F. (1992). Expression of a glutamate-activated chloride current in *Xenopus* oocytes injected with *Caenorhabditis elegans* RNA: evidence for modulation by avermectin. *Mol. Brain Res.*, 15, 339–348.
- ARENA, J.P., LIU, K.K., PARESS, P.S., FRAZIER, E.G., CULLY, D.F., MROZIK, H. & SCHAEFFER, J.M. (1995). The mechanism of action of avermeetins in *Caenorhabditis elegans* – correlation between activation of glutamate-sensitive chloride current, membrane-binding, and biological-activity. *J. Parasitol.*, 81, 286–294.
- BARGMANN, C.I. (1998). Neurobiology of the *Caenorhabditis* elegans genome. Science, 282, 2028-2033.
- BECKER, C.M. (1992). Convulsants acting at the inhibitory glycine receptor. In *Handbook of Experimental Pharmacology*. eds. Born, G.V.R., Cuatrecass, P. & Herken, H. Springer-Verlag, Heidelberg, pp. 539-575.
- BLOOMQUIST, J.R. (1993). Toxicology, mode of action and target site-mediated resistance to insecticides acting on chloride channels. *Comp. Biochem. Physiol. Ser. C*, **106**, 301–314.
- CASIDA, J.E. (1993). Insecticide action at the GABA-gated chloride channel: recognition, progress and prospects. *Arch. Insect Biochem. Physiol.*, **22**, 13–23.
- C. ELEGANS SEQUENCING CONSORTIUM. (1998). Genome sequence of the nematode C. elegans: a platform for investigating biology. Science, **282**, 2012–2017.
- CLELAND, T.A. (1996). Inhibitory glutamate receptor channels. *Mol. Neurobiol.*, **13**, 97–136.
- COLE, L.M., ROUSH, R.T. & CASIDA, J.E. (1993). Action of phenylpyrazole insecticides at the GABA-gated chloride channel. *Pestic. Biochem. Physiol.*, **46**, 47–54.
- CULL-CANDY, S.G. (1976). Two types of extrajunctional Lglutamate receptors in locust muscle fibres. J. Physiol. (Lond.), 255, 449-464.
- CULLY, D.F., PARESS, P.S., LIU, K.K., SCHAEFFER, J.S. & ARENA, J.P. (1996). Identification of a *Drosophila melanogaster* glutamate-gated chloride channel sensitive to the antiparasitic agent avermectin. J. Biol. Chem., 271, 20187-20191.
- CULLY, D.F., VASSILATIS, D.K., LIU, K.K., PARESS, P.S., VAN DER PLOEG, L.H.T., SCHAEFFER, J.S. & ARENA, J.P. (1994). Cloning of an avermectin-sensitive glutamate-gated chloride channel from *Caenorhabditis elegans*. *Nature*, **371**, 707–711.
- DENG, Y., PALMER, C.J. & CASIDA, J.E. (1993). House fly head GABA-gated chloride channels: four putative insecticide binding sites differentiated by [³H]EBOB and [³⁵S]TBPS. *Pestic. Biochem. Physiol.*, 47, 98–112.
- DENT, J.A., DAVIS, M.W. & AVERY, L. (1997). *avr-15* encodes a chloride channel subunit that mediates inhibitory glutamatergic transmission and ivermectin sensitivity in *Caenorhabditis elegans*. *EMBO J.*, **16**, 5867–5879.
- DENT, J.A., SMITH, M.M., VASSILATIS, D.K. & AVERY, L. (2000). The genetics of ivermectin resistance in *Caenorhabditis elegans*. *Proc. Natl. Acad. Sci. U.S.A.*, **97**, 2674–2679.
- ETTER, A., CULLY, D.F., LIU, K.K., REISS, B., VASSILATIS, D.K., SCHAEFFER, J.M. & ARENA, J.P. (1999). Picrotoxin blockade of invertebrate glutamate-gated chloride channel subunits: subunit dependence and evidence for binding within the pore. J. Neurochem., **72**, 318-326.
- FFRENCH-CONSTANT, R.H., ROCHELEAU, T.A., STEICHEN, J.C. & CHALMERS, A.E. (1993). A point mutation in a *Drosophila* GABA receptor confers insecticide resistance. *Nature*, **363**, 449 451.
- GURLEY, D., AMIN, J., ROSS, P.C., WEISS, D.S. & WHITE, G. (1995). Point mutations in the M2 region of the α , β or γ subunit of the GABA_A channel that abolish block by picrotoxin. *Receptors Channels*, **3**, 13–20.
- HAMON, A., LE CORRONC, H., HUE, B., RAUH, J.J. & SATTELLE, D.B. (1998). BIDN, a bicylic dinitrile convulsant, selectively blocks GABA-gated Cl⁻ channels. *Brain Res.*, **780**, 20–26.

- HOSIE, A.M., ARONSTEIN, K., SATTELLE, D.B. & FFRENCH-CONSTANT, R.H. (1997). Molecular biology of insect neuronal GABA receptors. *Trends Neurosci.*, 20, 578-583.
- HOSIE, A.M., BAYLIS, H.A., BUCKINGHAM, S.D. & SATTELLE, D.B. (1995). Actions of the insecticide, fipronil, on dieldrin-sensitive and -resistant GABA receptors of *Drosophila melanogaster*. Br. J. Pharmacol., **115**, 909–912.
- HOSIE, A.M., OTOE, Y., KOIKE, K., OTIMOTO, T., NIKAIDO, T. & SATTELLE, D.B. (1996). Action of picrodendrin antagonists on dieldrin-sensitive and -resistant *Drosophila* GABA receptors. *Br. J. Pharmacol.*, **119**, 1569–1576.
- LAUGHTON, D.L., LUNT, G.G. & WOLSTENHOLME, A.J. (1997). Alternative splicing produces two novel inhibitory amino acid receptor subunits from *Caenorhabditis elegans* with identical ligand-binding domains but different ion channels. *Gene*, **201**, 119-125.
- LYNCH, J.W., RAJENDRA, S., BARRY, P.H. & SCHOFIELD, P.R. (1995). Mutations affecting the glycine receptor agonist transduction mechanism convert the competitive antagonist, picrotoxin, into an allosteric potentiator. J. Biol. Chem., 270, 13799-13806.
- OLSEN, R. & TOBIN, A. (1990). Molecular biology of GABA_A receptors. *FASEB J.*, **4**, 1469–1480.
- PRIBILLA, I., TAKAGI, T., LANGOSCH, D., BORMANN, J. & BETZ, H. (1992). The atypical M2 segment of the β -subunit confers picrotoxinin resistance to inhibitory glycine receptors. *EMBO J.*, **11**, 4305–4311.
- RANGANATHAN, R., CANNON, S.C. & HORVITZ, H.R. (2000). MOD-1 is a serotoningated chloride channel that modulates locomotory behaviour in. C. elegans. Nature, 408, 470–475.
- RAUH, J.J., BENNER, E., SCHNEE, M.E., CORDOVA, D., HOLYOKE, C.W., HOWARD, M.H., BAI, D.L., BUCKINGHAM, S.D., HUTTON, M.L., HAMON, A., ROUSH, R.T. & SATTELLE, D.B. (1997). Effects of [³H]-BIDN, a novel bicyclic dinitrile radioligand for GABAgated chloride channels of insects and vertebrates. *Br. J. Pharmacol.*, **121**, 1496-1505.
- SHIRAI, Y., HOSIE, A.M., BUCKINGHAM, S.D., RAUH, J.J., ROUSH, R.T., BAYLIS, H.A. & SATTELLE, D.B. (1995). Blocking actions of BIDN, a bicyclic dinitrile convulsant compound, on wild-type and dieldrin-resistant GABA (Rdl) receptors of *Drosophila melanogaster* expressed in *Xenopus* oocytes. *Brain Res.*, 693, 257-260.
- SMITH, G.B. & OLSEN, R.W. (1995). Functional domains of GABA_A receptors. *Trends Pharmacol. Sci.*, 16, 163–168.
- VASSILATIS, D.K., ARENA, J.P., PLASTERK, R.H.A., WILKINSON, H., SCHAEFFER, J.M., CULLY, D.F. & VAN DER PLOEG, L.H.T. (1997). Genetic and biochemical evidence for a novel avermectinsensitive chloride channel in *Caenorhabditis elegans* – isolation and characterization. J. Biol. Chem., 272, 33167–33174.
- WANG, T.-L., HACKAM, A.S., GUGGINO, W.B. & CUTTING, G.R. (1995). A single amino acid in the γ-aminobutyric acid ρ1 receptor affects competitive and noncompetitive components of picrotoxin inhibition. *Proc. Natl. Acad. Sci. U.S.A.*, **92**, 11751– 11755.
- XU, M., COVEY, D.F. & AKABAS, M.H. (1995). Interaction of picrotoxin with GABA_A receptor channel-lining residues probed in cysteine mutants. *Biophys. J.*, 69, 1858–1867.
- ZHANG, H.-G., FFRENCH-CONSTANT, R.H. & JACKSON, M.B. (1994). A unique amino acid of the *Drosophila* GABA receptor with influence on drug sensitivity by two mechanisms. J. Physiol. (Lond.), 479, 65-75.
- ZHANG, H.-G, LEE, H.J., ROCHELEAU, T., FFRENCH-CONSTANT, R.H. & JACKSON, M.B. (1995). Subunit composition determines picrotoxin and bicuculline sensitivity of *Drosophila* γ-aminobutyric-acid receptors. *Mol. Pharmacol.*, 48, 835–840.
- ZHENG, Y., HIRSCHBERG, B., WANG, A., HUNT, D., YUAN, J., LUDMERER, S. & CULLY, D. (2000). Cloning and characterization of two novel histamine-gated chloride channel genes from. *Drosophila melanogaster. Soc. Neurosci. Abs.*, 26, 917.

(Received June 20, 2000 Revised December 14, 2000 Accepted January 8, 2001)